Turning the Tide on Cancer

Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Our goal is to overcome resistance, extend duration of response and increase overall survival.

focusing on cancer indications with the greatest medical need for new treatments

Featured News

June 15, 2020

Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML

June 9, 2020

Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

May 29, 2020

Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO

Targeting a Key Regulatory Enzyme in Tumor Cell Division

We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1), which is over expressed in most cancers.

Our Clinical Programs

Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.

KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase overalll survival.